|   | |
| Clinical data | |
|---|---|
| Other names | ABBV-552; ABBV552; SDI-118; SDI118 | 
|  Routes of administration  | Oral [1] | 
| Drug class | Synaptic vesicle glycoprotein 2A (SV2A) ligand [2] | 
| Identifiers | |
  | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H10ClF3N4O | 
| Molar mass | 330.70 g·mol−1 | 
| 3D model (JSmol) | |
  | |
  | |
Plosaracetam (INN ; developmental code names ABBV-552, SDI-118) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of Alzheimer's disease and other cognition disorders. [1] [3] [4] [2] In contrast to earlier SV2A ligands like levetiracetam and brivaracetam, polsaracetam does not have anticonvulsant activity and instead shows pro-cognitive effects. [2] The drug is being developed by UCB Biopharma and AbbVie. [1] [3] As of October 2024, it is in phase 2 clinical trials for Alzheimer's disease and phase 1 trials for cognition disorders. [1] [3]